7 news items
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ABBV
18 Jun 24
patients with ulcerative colitis, it's important to prioritize both early and sustained clinical remission as well as endoscopic improvement," said
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
ABBV
CI
CVS
7 Jun 24
. over the past year, Reuters reports.
This raises concerns among drug pricing experts and analysts about the sustainability
Halozyme's ENHANZE Product Gets New Patent Grant in EU
ABBV
ABOS
ALXO
6 Jun 24
and sustained revenues from this partnership.
For other ENHANZE licenses, Halozyme does not expect the new patent to impact the existing
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
ABBV
CRBP
CRDL
14 May 24
sustainable and pure cannabinoid products.
Cardiol Therapeutics Inc
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
ABBV
ATNM
AZN
22 Apr 24
of sustained outperformance, especially if interest rates trend downwards coupled with continuous innovation and active M
m3lugbzynyi706wmac62j7
ABBV
18 Apr 24
treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared
li4lh2odm6rnzfx3z1ghc
ABBV
18 Apr 24
) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo
- Prev
- 1
- Next